HIV Vaccines

艾滋病毒疫苗

• 批准号: 9065066
• 负责人: DAVID L. WOODLAND
• 金额: $ 2.16万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9065066
• 关键词: AIDS prevention; Active Immunization; Address; Adjuvant; Antibodies; Antibody Response; Antigens; Area; Awareness; B-Lymphocytes; Basic Science; California; Clinical Trials; Complex; Development; Epitopes; Equilibrium; Event; Future; Goals; Growth; HIV; HIV Infections; HIV vaccine; Health Priorities; Immunity; Immunoglobulins; Immunologics; Immunotherapy; Infection; Infection prevention; Intervention; Knowledge; Learning; Mucosal Immunity; Outcome; Passive Immunization; Pathogenesis; Pathway interactions; Play; Polysaccharides; Prevention; Prevention strategy; Productivity; Regulatory Pathway; Research; Research Personnel; Risk; Role; Scientist; Specificity; Staging; Structure; Therapeutic; Time; Traction; Translating; Translational Research; Vaccine Design; Vaccines; Viral Antibodies; Work; base; career; global health; graduate student; interest; meetings; neutralizing antibody; nonhuman primate; novel vaccines; posters; preclinical evaluation; preclinical study; preclinical trial; prevent; public health relevance; research clinical testing; research study; symposium; treatment strategy; vector; viral transmission

 DESCRIPTION (provided by the applicant): Support is requested for a Keystone Symposia meeting entitled HIV Vaccines, organized by David C. Montefiori and Mario Roederer. The meeting will be held in Olympic Valley, California from March 20-24, 2016. The development of a safe and effective HIV vaccine remains a major global health priority and a complex problem to solve. Current efforts emphasize an ability to elicit systemic and mucosal antibody responses capable of preventing the acquisition of infection. Evidence from multiple passive transfer experiments in nonhuman primates, as well as from studies of immunologic correlates of modest efficacy in the RV144 Thai trial, support the notion that both neutralizing and non-neutralizing antibodies have potential to prevent infection. Major advances have been made in understanding the epitopes, structures and evolutionary pathways of broadly neutralizing antibodies, leading to new avenues to pursue for vaccine design. The extraordinary breadth and potency of some recently discovered neutralizing antibodies has generated additional interest in potential therapeutic applications, including cure strategies. There has also been a steady increase in knowledge of other types of antiviral antibodies and their effector functions that may be important for vaccines. This meeting aims to cover a range of topics including: 1) Initial virus transmission events for vaccine intervention, 2) Non-neutralizing antibody correlates of sterilizing immunity; 3) Epitopes, structures and ontogeny of broadly neutralizing antibodies; 4) Novel vaccine concepts for broadly neutralizing antibody induction; and 5) Immunotherapy. Emphasis will be placed on recent unpublished findings in key areas that hold the greatest promise for rapid progress toward an effective vaccine. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on HIV Persistence: Pathogenesis and Eradication, which will share Keynote addresses and two plenary sessions with this meeting.

 描述（由申请人提供）：请求支持由 David C. Montefiori 和 Mario Roederer 组织的题为 HIV 疫苗的 Keystone 研讨会。会议将于 2016 年 3 月 20 日至 24 日在加利福尼亚州奥林匹克谷举行。开发安全有效的 HIV 疫苗仍然是全球卫生的主要优先事项，也是一个需要解决的复杂问题。目前的努力强调能够引发能够预防感染的全身和粘膜抗体反应。来自非人灵长类动物的多次被动转移实验的证据，以及 RV144 Thai 试验中适度功效的免疫相关研究的证据，支持中和抗体和非中和抗体都有可能预防感染的观点。在了解广泛中和抗体的表位、结构和进化途径方面取得了重大进展，为疫苗设计开辟了新途径。最近发现的一些中和抗体的非凡广度和效力引起了人们对潜在治疗应用（包括治愈策略）的更多兴趣。人们对其他类型的抗病毒抗体及其效应器功能的了解也不断增加，这对疫苗可能很重要。本次会议旨在涵盖一系列主题，包括：1）初始病毒 疫苗干预的传播事件，2）非中和抗体与灭菌免疫相关； 3) 广泛中和抗体的表位、结构和个体发育； 4）用于广泛中和抗体诱导的新疫苗概念； 5) 免疫疗法。重点将放在关键领域最近未发表的发现，这些发现最有希望快速开发出有效的疫苗。同期举行的艾滋病毒持续性：发病机制和根除会议将大大增加跨学科互动的机会，该会议将与本次会议分享主题演讲和两场全体会议。